Update on skin cancer incidence and mortality in Europe

The epidemiology of skin cancer shows interplay between host susceptibility, (ultraviolet) environment, socioeconomical conditions and behavioural patterns. Its etiology is not yet fully elucidated and reveals intriguing questions. Fair-skinned populations have experienced over the last 60 years a rapid increase in the incidence of melanoma which is unparalleled by any other cancer, although signs of levelling off and stabilization in incidence have recently been observed in some countries. Despite many primary prevention and early detection campaigns over the last decades in Europe, decreases in melanoma mortality are modest and limited to a few countries. Further, reduction in the incidence of thick melanomas has not yet been evidenced. In this presentation, drivers for the incidence and mortality trends of skin cancer, with a strong focus on melanoma, its most lethal form, will be discussed.

Public perceptions of animal experimentation across Europe

The goal of this article is to map out public perceptions of animal experimentation in 28 European countries. Postulating cross-cultural differences, this study mixes country-level variables (from the Eurostat database) and individual-level variables (from Eurobarometer Science and Technology 2010). It is shown that experimentation on animals such as mice is generally accepted in European countries, but perceptions are divided on dogs and monkeys. Between 2005 and 2010, we observe globally a change of approval on dogs and monkeys, with a significant decrease in nine countries. Multilevel analysis results show differences at country level (related to a post-industrialism model) and at individual level (related to gender, age, education, proximity and perceptions of science and the environment). These results may have consequences for public perceptions of science and we call for more cross-cultural research on press coverage of animal research and on the level of public engagement of scientists doing animal research

Health correlates of overweight and obesity in adults aged 50 years and over: results from the Survey of Health, Ageing and Retirement in Europe (SHARE)

QUESTIONS UNDER STUDY: To examine the association between overweight/obesity and several self-reported chronic diseases, symptoms and disability measures. METHODS: Data from eleven European countries participating in the Survey of Health, Ageing and Retirement in Europe were used. 18,584 non-institutionalised individuals aged 50 years and over with BMI > or = 18.5 (kg/m2) were included. BMI was categorized into normal weight (BMI 18.5-24.9), overweight (BMI 25.0-29.9) and obesity (BMI > or = 30). Dependent variables were 13 diagnosed chronic conditions, 11 health complaints, subjective health and physical disability measures. For both genders, multiple logistic regressions were performed adjusting for age, socioeconomic status and behaviour risks. RESULTS: The odds ratios for high blood pressure, high cholesterol, diabetes, arthritis, joint pain and swollen legs were significantly increased for overweight and obese adults. Compared to normal-weight individuals, the odds ratio (OR) for reporting > or = 2 chronic diseases was 2.4 (95% CI 1.9-2.9) for obese men and 2.7 (95% CI 2.2-3.1) for obese women. Overweight and obese women were more likely to report health symptoms. Obesity in men (OR 0.5, 95% CI 0.4-0.6), and overweight (OR 0.5, 95% CI 0.4-0.6) and obesity (OR 0.4, 95% CI 0.3-0.5) in women, were associated with poorer subjective health (i.e. a decreased risk of reporting excellent, very good or good subjective health). Disability outcomes were those showing the greatest differences in strength of association across BMI categories, and between genders. For example, the OR for any difficulty in walking 100 metres was non-significant at 0.8 for overweight men, at 1.9 (95% CI 1.3-2.7) for obese men, at 1.4 (95% CI 1.1-1.8) for overweight women, and at 3.5 (95% CI 2.6-4.7) for obese women. CONCLUSIONS: These results highlight the impact of increased BMI on morbidity and disability. Healthcare stakeholders of the participating countries should be aware of the substantial burden that obesity places on the general health and autonomy of adults aged over 50.

Identifying the gap between need and intervention for alcohol use disorders in Europe.

AIMS: A literature review of existing research on the prevalence of alcohol use disorders (AUDs) and availability of alcohol interventions in Europe was conducted. The review also explored what is known about the gap between need and provision of alcohol interventions in Europe. METHODS: The review search strategy included: (i) descriptive studies of alcohol intervention systems in Europe; (ii) studies of alcohol service provision in Europe; and (iii) studies of prevalence of AUD and alcohol needs assessment in Europe. RESULTS: Europe has a relatively high level of alcohol consumption and the resulting disabilities are the highest in the world. Most research on implementation of alcohol interventions in Europe has been restricted to screening and brief interventions. Alcohol needs assessment methodology has been developed but has not been applied in comparative studies across countries in Europe. CONCLUSIONS: This review points to key gaps in knowledge related to alcohol interventions in Europe. There is a lack of comparative data on variations in alcohol treatment systems across European countries and there is also a lack of comparative data on the prevalence of alcohol use disorders across European countries and the relative gap between need and access to treatment. The forthcoming Alcohol Measures for Public Health Research Alliance (AMPHORA) research project work package on 'Early identification and treatment' aims to address these gaps.

Quartiers durables en Europe : enjeux sociaux et processuels

Verena Schaeffer, Jean Ruegg et Natacha Litzistorf Spina ont analysé les enjeux sociaux et processuels d'une douzaine de quartiers durables en Europe. Leur article s'appuie sur une recherche /1 faite dans le cadre du projet-modèle suisse "Des quartiers durables pour l'agglomération lausannoise". Il pointe la complexité de la mise en oeuvre du développement durable urbain à l'échelle de quartiers modèles, tout en soulignant leur intérêt comme démarche d'apprentissage pour des villes durables.

Ombres d'Europe. Tanizaki ou l'éloge opaque

(Résumé de l'ouvrage) C'est grâce aux portulans - ces cartes géographiques qui permettaient la navigation de port à port avec l'indication exacte de l'échelle des distances - que les navigateurs purent disposer d'une représentation beaucoup plus fidèle des côtes maritimes. Le portulan a permis au marin d'abandonner le cabotage craintif qui l'obligeait à naviguer le long des côtes, toujours tenues à distance de regard, pour la navigation en haute mer. Aujourd'hui la représentation de l'Europe est une inconnue. Le cabotage n'est plus de mise, mais le portulan manque. Nul ne peut dire où il faut commencer et où il faut jeter l'ancre. L'Europe est comme libérée de ses voeux, débordée en mille endroits. Europes intempestives présente neuf textes qui dressent une carte en filigrane, selon les termes d'une échelle inconnue qui doit faire passer pour saugrenue toute personne qui demande : « Qu'est-ce que l'Europe ? ». Il s'agit pour nous de sortir du cadastre de ce qu'il faut appeler une rhétorique Europe, avec ses métaphores fatiguées, frêles esquifs sur une mer de clichés : cap, parapet, occident, coucheries solaires et rapt.

La place de la supervision en thérapie comportementale et cognitive en Europe

La formation en psychothérapie comportementale et cognitive en Europe suit des exigences variées selon les pays, malgré les standards communs de formation dans ce domaine émis par l'EABCT. En général les pays qui ont une réglementation légale de la psychothérapie ont des critères de reconnaissance plus sévères que ceux de l'EABCT, alors que les autres tendent à s'aligner sur les règles de l'Association. Dans les programmes de formation, le rôle de la supervision varie également d'un pays à l'autre. Ces variations touchent aussi bien la quantité de supervisions demandées, ses modalités d'application, que les critères de reconnaissance des superviseurs. L'EABCT a récemment publié des recommandations pour la reconnaissance des superviseurs, pour garantir que les superviseurs soient spécifiquement formés à cette activité. Ces critères sont plus sévères que ceux de la plupart des associations de TCC ou des règlementations nationales du titre de psychothérapeute, ce qui peut poser des problèmes d'implémentation, même dans les pays qui disposent d'une législation en matière de psychothérapie. Nous assistons à une tendance allant vers une professionnalisation plus grande de l'activité de supervision. Cette professionnalisation, pour autant qu'elle soit scientifiquement fondée, mérite sans doute d'être défendue. Il s'agira cependant d'être attentif au fait qu'un excès de règlements ne bloque pas les possibilités de formation et par conséquence la diffusion des TCC, notamment dans les régions où elles sont encore peu implantées.

Contribution of ultrasonographic examination to the prenatal detection of chromosomal abnormalities in 19 centres across Europe.

The objective of this study was to evaluate the prenatal detection of chromosomal abnormalities by fetal ultrasonographic examination in a large database provided by 19 Registries of Congenital Anomalies from 11 European countries. This study included 1738 cases of chromosomal abnormalities, liveborn, stillborn or termination of pregnancy regardless of maternal age from a population of 664,340 births during the period 1996 - 1998. The most frequent chromosomal anomalies were Down syndrome (n=1050), trisomy 18 (n=191), Turner syndrome (n=125), trisomy 13 (n=86), and triploidy (n=56). Fetal ultrasonographic examination resulted in the prenatal detection of 37.7% of the chromosomal abnormalities, thereby resulting in a reduction of 28.6% in their prevalence at birth due to terminations of pregnancy. The detection rate by ultrasound examination varied according to local policies of prenatal diagnosis : it was lower in countries where routine scan were not performed and higher in countries in which at least one routine anomaly scan during the second trimester of pregnancy was performed. The ultrasound detection varied according to the specific chromosomal anomaly and was lowest for Klinefelter syndrome (5.7%) and highest for triploidy (78.6%). For Down syndrome it was 26.4%. Termination of pregnancy was performed in 75.9% of the cases. Among the 655 cases detected by ultrasound, the most frequent ultrasound signs by category of chromosomal abnormalities were analysed. This study shows that ultrasound screening is an important tool in the prenatal detection of chromosomal abnormalities in Europe, leading to a significant reduction in the prevalence of livebirth children with chromosomal anomalies.

European Council of Legal Medicine (ECLM) accreditation of forensic pathology services in Europe.

Forensic experts play a major role in the legal process as they offer professional expert opinion and evidence within the criminal justice system adjudicating on the innocence or alleged guilt of an accused person. In this respect, medico-legal examination is an essential part of the investigation process, determining in a scientific way the cause(s) and manner of unexpected and/or unnatural death or bringing clinical evidence in case of physical, psychological, or sexual abuse in living people. From a legal perspective, these types of investigation must meet international standards, i.e., it should be independent, effective, and prompt. Ideally, the investigations should be conducted by board-certified experts in forensic medicine, endowed with a solid experience in this field, without any hierarchical relationship with the prosecuting authorities and having access to appropriate facilities in order to provide forensic reports of high quality. In this respect, there is a need for any private or public national or international authority including non-governmental organizations seeking experts qualified in forensic medicine to have at disposal a list of specialists working in accordance with high standards of professional performance within forensic pathology services that have been successfully submitted to an official accreditation/certification process using valid and acceptable criteria. To reach this goal, the National Association of Medical Examiners (NAME) has elaborated an accreditation/certification checklist which should be served as decision-making support to assist inspectors appointed to evaluate applicants. In the same spirit than NAME Accreditation Standards, European Council of Legal Medicine (ECLM) board decided to set up an ad hoc working group with the mission to elaborate an accreditation/certification procedure similar to the NAME's one but taking into account the realities of forensic medicine practices in Europe and restricted to post-mortem investigations. This accreditation process applies to services and not to individual practitioners by emphasizing policies and procedures rather than professional performance. In addition, the standards to be complied with should be considered as the minimum standards needed to get the recognition of performing and reliable forensic pathology service.

Les maladies rares affectent 30 millions de personnes en Europe

En Europe, une maladie est dite rare lorsqu'elle affecte moins d'une personne sur 2000. C'est une affection invalidante pouvant mettre en jeu le pronostic vital et qui nécessite des efforts combinés spéciaux pour sa prise en charge. Plus de 7000 maladies rares ont été identifiées à ce jour. Prises dans leur ensemble, elles affectent 30 millions de personnes en Europe et constituent un problème majeur de santé publique. L'Union européenne et de nombreux Etats membres ont déjà pris des mesures spécifiques de grande ampleur pour lutter contre les maladies rares, mais cette problématique est encore largement méconnue en Suisse. La première Journée européenne des maladies rares invite les autorités politiques suisses, les professionnels de santé, les scientifiques et l'industrie pharmaceutique à soutenir les efforts déjà initiés et progresser dans la lutte contre les maladies rares dans notre pays.